Anastrozol
| Evidensnivå: L5 | Förutsagda indikationer: 0 st |
Innehållsförteckning
Anastrozol: Drug Repurposing Evaluation Report
One-Sentence Summary
Anastrozol (anastrozole) is a well-known non-steroidal aromatase inhibitor, widely used internationally for the treatment of hormone receptor-positive breast cancer. The TxGNN model has not yet generated any predicted new indications for this compound, and the Evidence Pack currently contains significant data gaps across regulatory, safety, and mechanistic domains.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in evidence pack (internationally known for hormone receptor-positive breast cancer) |
| Predicted New Indication | None predicted |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction not yet available |
| Taiwan Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, no TxGNN prediction has been generated for Anastrozol. Without a predicted new indication, a mechanistic plausibility assessment cannot be performed at this time.
Based on publicly available knowledge, anastrozole is a potent and selective third-generation aromatase inhibitor that blocks the conversion of androgens to estrogens by inhibiting the cytochrome P450 enzyme aromatase (CYP19A1). This mechanism makes it a cornerstone therapy in postmenopausal hormone receptor-positive breast cancer. The detailed mechanism of action (MOA) entry in this evidence pack is flagged as a data gap and needs to be populated from DrugBank or equivalent sources before further evaluation.
Given the absence of any predicted indications from TxGNN, no drug–disease mechanistic linkage can be evaluated. This evidence pack should be considered a preliminary scaffold that requires substantial data enrichment before it can support a repurposing assessment.
Clinical Trial Evidence
Currently no related clinical trials registered in the evidence pack. No TxGNN-predicted indication is available to anchor a clinical trial search.
Literature Evidence
Currently no related literature available in the evidence pack. Once a predicted indication is generated by TxGNN, a targeted literature search should be conducted.
Taiwan Market Information
Anastrozol currently holds no marketing authorizations in Taiwan (TFDA). No license records were found.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| — | — | — | No Taiwan authorizations on file |
Note: Anastrozole is marketed in many other countries (e.g., as Arimidex® by AstraZeneca). The absence of Taiwan authorizations may affect the feasibility of local repurposing initiatives.
Cytotoxicity
Anastrozole is an aromatase inhibitor used in oncology (breast cancer). While it is an antineoplastic agent, it is not a conventional cytotoxic drug — it is classified as a targeted endocrine therapy.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted endocrine therapy (aromatase inhibitor), not conventional cytotoxic |
| Myelosuppression Risk | Low (not typically associated with significant myelosuppression) |
| Emetogenicity Classification | Low (minimal emetogenic potential) |
| Monitoring Items | Bone mineral density (osteoporosis risk), lipid profile, liver function, musculoskeletal symptoms |
| Handling Protection | Standard handling; does not require cytotoxic drug handling precautions |
Safety Considerations
Please refer to the package insert for safety information. All safety fields (key warnings, contraindications, drug interactions) are currently flagged as data gaps in the evidence pack and require population from TFDA package insert or DrugBank sources.
Critical Data Gaps Identified:
- DG001 (Blocking): TFDA package insert warnings/contraindications not yet retrieved — this blocks the Stage 1 safety assessment.
- DG002 (High): Mechanism of action (MOA) not yet documented — this impacts mechanistic relevance analysis for any future predicted indications.
Conclusion and Next Steps
Decision: Hold
Rationale: No TxGNN predicted indications have been generated for Anastrozol, and the evidence pack has critical data gaps at the drug level (MOA, safety warnings, contraindications). Without a predicted indication, the repurposing evaluation cannot proceed beyond the data preparation stage.
To proceed, the following is needed:
- Run TxGNN prediction pipeline for Anastrozol to generate candidate new indications
- Retrieve and parse the DrugBank entry to populate MOA, DrugBank ID, and pharmacological classification (Remediation: query DrugBank API as noted in DG002)
- Obtain TFDA package insert data or, if not marketed in Taiwan, reference international regulatory documents (EMA/FDA) for safety profile (Remediation: as noted in DG001)
- Once a predicted indication is available, conduct targeted clinical trial and literature searches (ClinicalTrials.gov, PubMed)
- Reassess market access strategy given the drug is not currently authorized in Taiwan
Ansvarsfriskrivning
Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning. Klinisk validering krävs före klinisk tillämpning.